Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension of ECU-MG-301: long-term eculizumab in refractory generalized myasthenia gravis
2013-002191-41Phase 3Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Jul 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of eculizumab in myasthenia gravis (MG), sponsored by Alexion Pharmaceuticals. Primary endpoint: Change from baseline in MG-ADL total score. Started Jul 2014; status: completed.
02
Drugs
eculizumab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on 2013-002191-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002191-41.